Formulation of meloxicam gel for topical application: In vitro and in vivo evaluation
By: Yogeshwar Bachhav and Vandana Patravale
Open Access
|Dec 2010References
- S. Noble and J. A. Balfour, Meloxicam,(1996) 424-430; DOI: 10.2165/00003495-199651030-00007.
- N. M. Davies and N. M. Skjodt, Clinical pharmacokinetics of meloxicam: a cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug,(1999) 115-126; DOI: 2165/00003088-199936020-00003.
- B. J. Gates, T. T. Nguyen, S. M. Setter and N. M. Davies, Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety,(2005) 2117-2140; DOI: 10.1517/14656566.6.12.2117.
- M. R. Prausnitz, S. Mitragotri and R. Langer, Current status and future potential of transdermal drug delivery,(2004) 115-124; DOI: 10.1038/nrd1304.
- E. Beetge, J. D. Plessis, D. G. Muller, C. Goosen and F. J. Van Rensburg, The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAIDs on their transdermal absorption,(2000) 261-264; DOI: 10.1016/S0378-5173(99)00340-3.
- P. Stei, B Kruss, J. Weigleb and V. Trach, Local tissue tolerability of meloxicam, a new NSAID: indications for parenteral, dermal and mucosal administration,(1996) 44-50; DOI: 10.1093/rheumatology/35.suppl_1.44.
- R. Jantharaprapap and G. Stagni, Effects of penetration enhancers on in vitro permeability of meloxicam gels,(2007) 26-33; DOI: 10.1016/j.ijpharm.2007.04.011.
- J. S. Chang, Y. B. Huang, S. S. Hou, R. J. Wang, P. C. Wu and Y. H. Tsai, Formulation optimization of meloxicam sodium gel using response surface methodology,(2007) 48-54; DOI: 10.1016/j.ijpharm.2007.01.033.
- Y. Yuan, S. M. Li, F. K. Mo and D. F. Zhong, Investigation of microemulsion system for transdermal delivery of meloxicam,(2006) 117-123; DOI: 10.1016/j.ijpharm.2006.06.021.
- , International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva 2005, Switzerland.
- M. Joshi and V. Patravale, Nanostructured lipid carrier (NLC) based gel of celecoxib,(2008) 124-132; DOI: 10.1016/j.ijpharm.2007.05.060.
- , USP Pharmacopoeial Convention, Rockwille (MD) 2000.
- ICH Topic Q1 A (R2) Stability Testing of new Drug Substances and Products (2005), International Conference on Harmonisation of Technical requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland.
- B. J. Vermeer, Skin irritation and sensitization,(1991) 261-265; DOI: 10.1016/0168-3659(91)90117-V.
- E. Pontiki and D. Hadjipavlou-Litina, Synthesis of phenyl-substituted amides with antioxidant and anti-inflammatory activity as novel lipoxygenase inhibitors,(2007) 175-186; DOI: 10.2174/157340607780059512.
- M. D. Joshi and V. B. Patravale, Formulation and evaluation of nanostructured lipid carrier (NLC) based gel of valdecoxib,(2006) 911-918; DOI: 10.1080/03639040600814676.
- R. Sanghavi, R. Narazaki, S. G. Machatha and S. H. Yalkowsky, Solubility improvement of drugs using N-methyl pyrrolidone,(2008) 366-376; DOI: 10.1208/s12249-008-9050-z.
- P. J. Lee, R. Langer and V. P. Shastri, Role of N-methyl pyrrolidone in the enhancement of aqueous phase transdermal transport,(2005) 912-917; DOI: 10.1002/jps.20291.
- A. C. Williams and B. W. Barry, Penetration enhancers,(2004) 603-618; DOI:10.1016/j.addr.2003.10.025.
Language: English, Croatian
Page range: 153 - 163
Published on: Dec 6, 2010
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Related subjects:
© 2010 Yogeshwar Bachhav, Vandana Patravale, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.